[Pubmed] Role of complement in myasthenia gravis

[RSS-Bot]

Front Neurol. 2023 Oct 5;14:1277596. doi: 10.3389/fneur.2023.1277596. eCollection 2023.

ABSTRACT

Myasthenia gravis is a prototypic neuroimmune disorder with autoantibodies targeting the acetylcholine receptor complex at the neuromuscular junction. Patients present with mainly ocular muscle weakness and tend to have a generalized muscle weakness later in the clinical course. The weakness can be severe and fatal when bulbar muscles are heavily involved. Acetylcholine receptor antibodies are present in the majority of patients and are of IgG1 and IgG3 subtypes which can activate the complement system. The complement involvement plays a major role in the neuromuscular junction damage and the supporting evidence in the literature is described in this article. Complement therapies were initially studied and approved for paroxysmal nocturnal hemoglobinuria and in the past decade, those have also been studied in myasthenia gravis. The currently available randomized control trial and real-world data on the efficacy and safety of the approved and investigational complement therapies are summarized in this review.

PMID:37869140 | PMC:PMC10585143 | DOI:10.3389/fneur.2023.1277596


Source: https://pubmed.ncbi.nlm.nih.gov/3786914 ... t6+86293ac